Recursion Pharmaceuticals (RXRX) recently reported below-expectation Q4 results, with a loss of $0.53 per share on revenue of $4.55 million. While these figures fell short of analyst predictions, the TechBio company revealed promising early results in its clinical programs, particularly REC 617 and REC 994, which sparked optimism. The company further expanded its trials, and maintains a solid financial position with a cash reserve of $600 million, underpinning its ongoing operations until 2027.
A Promising Pipeline
Recursion Pharmaceuticals is a clinical-stage TechBio company with an innovative approach to drug discovery by decoding biology. Utilizing advanced machine-learning algorithms, Recursion efficiently extracts trillions of searchable relationships from its dataset, eradicating human bias. The company is integrating technology with biology and chemistry to revolutionize the medical future by conducting millions of wet lab experiments weekly and operating a globally powerful supercomputer.
The company is currently experiencing growth and development, focusing primarily on clinical advancements, strategic collaborations, and innovative technology. Recursion has reported encouraging early results, especially with their REC-617 and REC-994 programs. REC-617 has shown initial efficacy signals in monotherapy, featuring a sustained decrease in tumor size in a patient over six months. On the other hand, REC-994 has demonstrated persistent safety and a promising reduction in lesion size in its Phase II study, representing a remarkable stride in their clinical program.
Simultaneously, the company is broadening its pipeline by introducing multiple trials, such as REC-1245, REK-4881, and REC-3964. These additions underline Recursion’s dedication to meeting varied medical requirements and boosting its therapeutic options.
Is RXRX a Buy?
For 2024, Recursion posted revenue of $58.8 million, a notable increase from the prior year’s $44.6 million, attributed to revenue recognized from their Roche and Genentech collaboration. Research and development expenses rose to $314.4 million in 2024 from $241.2 million due to the expansion and upgrade of their platform, helping to drive a net loss of $463.7 million.
Analysts following the company have been cautiously optimistic about its prospects. For example, Needham’s Gil Blum has recently reiterated a Buy rating on the shares with a price target of $11.00. Blum’s rating is backed by Recursion Pharmaceuticals’ broad capabilities and expansive internal data generation, positioning it as an industry leader. The company’s strategic use of AI-based ‘virtual cell’ models is expected to impact drug development significantly. While upcoming clinical readouts are anticipated to be progressive, they remain essential for validating Recursion’s platform and supporting an overall positive outlook for the stock.
Recursion Pharmaceuticals is rated a Moderate Buy overall, based on the recent recommendations of six analysts. The average price target for RXRX stock is $9.25, which represents a potential upside of 40.58% from current levels.
See more RXRX analyst ratings.
Questions or Comments about the article? Write to editor@tipranks.com